Firefly Neuroscience Joins NVIDIA Connect Program to Advance Brain Network Analytics

Firefly Neuroscience, Inc. (NASDAQ: AIFF), a pioneering artificial intelligence (AI) company specializing in innovative solutions for brain health, has announced its acceptance into the prestigious NVIDIA Connect program. This strategic partnership will provide Firefly with access to advanced software development resources, industry-leading frameworks, and global ecosystem support, enabling the company to further enhance its FDA-cleared Brain Network Analytics (BNA™) platform. In addition, Firefly unveils a new strategic initiative to build the world's first foundation model of the human brain using its BNA™ technology.

NVIDIA Connect brings together NVIDIA's advanced software development resources, industry-leading frameworks and software development kits, and global ecosystem to help fuel the growth of member companies and expand the capabilities of their software development teams. Benefits include technical training and engineering guidance to support the development of products, and discounts on NVIDIA software and hardware to accelerate development and increase efficiency.

"We are honored and excited to be among the select few medtech companies – big, medium or small – to be accepted into the prestigious NVIDIA Connect program," said Greg Lipschitz, Executive Chairman of Firefly. "This marks the achievement of an important milestone for Firefly and comes at an extremely opportune time. As our already unparalleled BNA™ database continues to grow with each new clinical study and/or clinical assessment in which our technology is used, and we have gained vital access to the best hardware and latest resources through the NVIDIA Connect program, we believe that Firefly is now uniquely positioned to build the world’s first foundation model of the human brain."

Firefly's BNA™ platform, developed using artificial intelligence and machine learning on the company's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome.

Firefly is an AI company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. The company's FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, secured patent protection, and achieved FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.

In conclusion, Firefly Neuroscience's acceptance into the NVIDIA Connect program and its new strategic initiative to build the world's first foundation model of the human brain using its BNA™ technology position the company at the forefront of neuroscience innovation. By leveraging advanced software development resources and technical training, Firefly aims to enhance its BNA™ platform and improve brain health outcomes for patients with neurological and mental disorders. As the company continues to grow its extensive brain wave database, it is well-positioned to make significant strides in the field of brain health and AI-driven solutions.